| Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity H Högel, E Rissanen, C Barro, M Matilainen, M Nylund, J Kuhle, L Airas Multiple Sclerosis Journal 26 (2), 210-219, 2020 | 147 | 2020 |
| Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis M Sucksdorff, M Matilainen, J Tuisku, E Polvinen, A Vuorimaa, J Rokka, ... Brain 143 (11), 3318-3330, 2020 | 114 | 2020 |
| Evaluation of microglial activation in multiple sclerosis patients using positron emission tomography L Airas, M Nylund, E Rissanen Frontiers in neurology 9, 181, 2018 | 71 | 2018 |
| Natalizumab treatment reduces microglial activation in the white matter of the MS brain M Sucksdorff, J Tuisku, M Matilainen, A Vuorimaa, S Smith, J Keitilä, ... Neurology-Neuroimmunology Neuroinflammation 6 (4), e574, 2019 | 52 | 2019 |
| Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging S Bezukladova, J Tuisku, M Matilainen, A Vuorimaa, M Nylund, S Smith, ... Neurology-Neuroimmunology Neuroinflammation 7 (3), 2020 | 34 | 2020 |
| Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET M Nylund, M Sucksdorff, M Matilainen, E Polvinen, J Tuisku, L Airas Brain Communications 4 (1), fcab301, 2022 | 26 | 2022 |
| Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland L Airas, M Nylund, I Mannonen, M Matilainen, M Sucksdorff, E Rissanen Multiple Sclerosis and Related Disorders 40, 101980, 2020 | 26 | 2020 |
| Innate Immune Cell–Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis O Misin, M Matilainen, M Nylund, E Honkonen, E Rissanen, M Sucksdorff, ... Neurology-Neuroimmunology Neuroinflammation 9 (4), 2022 | 17 | 2022 |
| TSPO-Detectable Chronic Active Lesions Predict Disease Progression in Multiple Sclerosis E Polvinen, M Matilainen, M Nylund, M Sucksdorff, LM Airas Neurology-Neuroimmunology Neuroinflammation 10 (5), 2023 | 7 | 2023 |
| Frequency and etiology of acute transverse myelitis in Southern Finland E Smith, N Jaakonmäki, M Nylund, L Kupila, M Matilainen, L Airas Multiple Sclerosis and Related Disorders 46, 102562, 2020 | 7 | 2020 |
| Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy M Nylund, T Vuorinen, L Airas Multiple Sclerosis and Related Disorders, 102058, 2020 | 7 | 2020 |
| Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis J Lehto, M Nylund, M Matilainen, M Sucksdorff, A Vuorimaa, J Rajander, ... European journal of neurology 30 (8), 2365-2375, 2023 | 3 | 2023 |
| PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report J Lehto, M Sucksdorff, M Nylund, R Raitanen, M Matilainen, L Airas Journal of Neurology 270 (4), 2329-2332, 2023 | 3 | 2023 |
| Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis S Laaksonen, M Saraste, M Sucksdorff, M Nylund, A Vuorimaa, ... Multiple Sclerosis and Related Disorders 75, 104755, 2023 | 2 | 2023 |
| Serum GFAP associates with neurofilament light and disease severity in late multiple sclerosis H Hogel, E Rissanen, C Barro, M Matilainen, M Nylund, J Kuhle, L Airas MULTIPLE SCLEROSIS JOURNAL 24, 658-659, 2018 | 1 | 2018 |
| Longitudinal stability of progression‐related microglial activity during teriflunomide treatment in patients with multiple sclerosis J Lehto, M Nylund, M Matilainen, M Sucksdorff, A Vuorimaa, J Rajander, ... European Journal of Neurology 30 (8), 2365-2375, 2023 | | 2023 |
| Impact of natalizumab on chronic active lesions (P11-3.011) M Nylund, M Matilainen, M Sucksdorff, E Polvinen, L Airas Neurology 100 (17 Supplement 2), 2023 | | 2023 |
| An in vivo study of microglial activation and astrocyte reactivity in MS brain by PET-imaging and concurrent use of two radioligands A Vuorimaa, M Matilainen, J Tuisku, M Nylund, E Rissanen, L Airas MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 542-542, 2022 | | 2022 |
| Impact of natalizumab on chronic active lesions M Nylund, M Matilainen, M Sucksdorff, E Polvinen, A Vuorimaa, L Airas MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 540-540, 2022 | | 2022 |
| Chronic lesion phenotyping provides a strong predictor for disease progression in multiple sclerosis E Polvinen, M Matilainen, M Nylund, M Sucksdorff, L Airas MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 118-118, 2022 | | 2022 |
